Drug Delivery Business

Vertex Pharmaceuticals wins FDA fast track designation for its cell-based diabetes treatment

By

Vertex PharmaceuticalsVertex Pharmaceuticals (Nasdaq: VRTX) announced today that FDA has granted fast track designation for its VX-880, an investigational human stem cell-derived islet cell therapy for type 1 diabetes.

Vertex has begun a clinical trial for VX-880 (formerly known as STx-02) in patients with type 1 diabetes (T1D) with severe hypoglycemia and impaired hypoglycemic awareness.

“Ours is the only approach that produces fully differentiated and fully functional insulin-secreting pancreatic islets,” said Bastiano Sanna, EVP and chief of Cell and Genetic Therapies at Vertex.

Get the full story on our sister site Drug Discovery and Development. 

IN CASE YOU MISSED IT

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].